Targeted drug aims to stop blood cancer return after transplant
Disease control
Ongoing
This phase 1 trial tests whether the drug tagraxofusp can help prevent relapse in people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis, or chronic myelomonocytic leukemia) who have recently received a stem cell transplant. Participant…
Phase: PHASE1 • Sponsor: Karen Ballen, MD • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC